Paul B. Watkins

30.6k total citations · 4 hit papers
246 papers, 19.9k citations indexed

About

Paul B. Watkins is a scholar working on Pharmacology, Oncology and Epidemiology. According to data from OpenAlex, Paul B. Watkins has authored 246 papers receiving a total of 19.9k indexed citations (citations by other indexed papers that have themselves been cited), including 167 papers in Pharmacology, 84 papers in Oncology and 51 papers in Epidemiology. Recurrent topics in Paul B. Watkins's work include Drug-Induced Hepatotoxicity and Protection (113 papers), Pharmacogenetics and Drug Metabolism (112 papers) and Drug Transport and Resistance Mechanisms (76 papers). Paul B. Watkins is often cited by papers focused on Drug-Induced Hepatotoxicity and Protection (113 papers), Pharmacogenetics and Drug Metabolism (112 papers) and Drug Transport and Resistance Mechanisms (76 papers). Paul B. Watkins collaborates with scholars based in United States, United Kingdom and Switzerland. Paul B. Watkins's co-authors include Steven Wrighton, Erin G. Schuetz, Philip S. Guzelian, Robert J. Fontana, Kenneth E. Thummel, Kenneth S. Lown, Mary F. Paine, Joseph C. Kolars, Timothy J. Davern and José Serrano and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and JAMA.

In The Last Decade

Paul B. Watkins

239 papers receiving 19.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

2001 1.8k citations Paul B. Watkins, Ann K. Daly et al. profile →
Causes, Clinical Features, and Outcomes From a Prospective Study of Drug-Induced Liver Injury in the United States

2008 638 citations Naga Chalasani, Robert J. Fontana et al. profile →
Hepatotoxic Effects of Tacrine Administration in Patients With Alzheimer's Disease

1994 612 citations Paul B. Watkins profile →
Drug-induced liver injury

2019 537 citations Raúl J. Andrade, Naga Chalasani et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paul B. Watkins United States	73	11.5k	6.2k	3.5k	3.2k	2.3k	246	19.9k
Ann K. Daly United Kingdom	74	9.9k 0.9×	4.5k 0.7×	4.3k 1.2×	2.3k 0.7×	4.1k 1.8×	282	20.5k
Ulrich M. Zanger Germany	74	10.1k 0.9×	6.8k 1.1×	5.1k 1.4×	3.1k 1.0×	1.2k 0.5×	197	19.8k
Philippe Beaune France	75	9.2k 0.8×	5.7k 0.9×	5.1k 1.4×	2.3k 0.7×	1.2k 0.5×	352	18.7k
Leslie Z. Benet United States	80	8.4k 0.7×	9.5k 1.5×	5.0k 1.4×	6.1k 1.9×	1.6k 0.7×	510	26.5k
Kenneth E. Thummel United States	73	11.5k 1.0×	7.2k 1.2×	3.1k 0.9×	4.7k 1.5×	870 0.4×	263	20.2k
Richard B. Kim Canada	74	5.7k 0.5×	9.1k 1.5×	3.7k 1.1×	4.7k 1.5×	1.5k 0.6×	243	18.5k
Erin G. Schuetz United States	77	9.8k 0.9×	9.7k 1.6×	4.7k 1.3×	4.0k 1.3×	958 0.4×	198	19.9k
Tsuyoshi Yokoi Japan	67	7.2k 0.6×	4.8k 0.8×	6.2k 1.8×	1.7k 0.5×	1.0k 0.4×	369	16.2k
Amin Rostami‐Hodjegan United Kingdom	71	6.5k 0.6×	4.9k 0.8×	2.7k 0.8×	3.7k 1.2×	953 0.4×	324	16.0k
Stephen D. Hall United States	63	6.4k 0.6×	4.4k 0.7×	2.2k 0.6×	2.2k 0.7×	1.2k 0.5×	217	14.1k

Countries citing papers authored by Paul B. Watkins

Since Specialization

Citations

This map shows the geographic impact of Paul B. Watkins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul B. Watkins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul B. Watkins more than expected).

Fields of papers citing papers by Paul B. Watkins

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul B. Watkins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul B. Watkins. The network helps show where Paul B. Watkins may publish in the future.

Co-authorship network of co-authors of Paul B. Watkins

This figure shows the co-authorship network connecting the top 25 collaborators of Paul B. Watkins. A scholar is included among the top collaborators of Paul B. Watkins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul B. Watkins. Paul B. Watkins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zaidman, Craig M., Amal Aqul, Russell J. Butterfield, et al.. (2024). Management of Select Adverse Events Following Delandistrogene Moxeparvovec Gene Therapy for Patients With Duchenne Muscular Dystrophy. Journal of Neuromuscular Diseases. 11(3). 687–699. 9 indexed citations

Beaudoin, James J., Kyunghee Yang, Jeffry Adiwidjaja, et al.. (2023). Investigating bile acid-mediated cholestatic drug-induced liver injury using a mechanistic model of multidrug resistance protein 3 (MDR3) inhibition. Frontiers in Pharmacology. 13. 1085621–1085621. 6 indexed citations

Kong, Ronald, et al.. (2023). Quantitative Systems Toxicology Modeling Informed Safe Dose Selection of Emvododstat in Acute Myeloid Leukemia Patients. Clinical Pharmacology & Therapeutics. 115(3). 525–534. 5 indexed citations

Nautiyal, Manisha, Caroline Bauch, Paul Walker, Paul B. Watkins, & Merrie Mosedale. (2020). Fit-For-Purpose Hepatocyte Models Enable the Identification of Early Events Contributing to Idelalisib-Induced Liver Injury. 6(4). 110–119. 1 indexed citations

Nicoletti, Paola, Harshad Devarbhavi, Ashish Goel, et al.. (2020). Genetic Risk Factors in Drug‐Induced Liver Injury Due to Isoniazid‐Containing Antituberculosis Drug Regimens. Clinical Pharmacology & Therapeutics. 109(4). 1125–1135. 40 indexed citations

Nguyen, Deborah G., et al.. (2019). Bioprinted liver provides early insight into the role of Kupffer cells in TGF-β1 and methotrexate-induced fibrogenesis. PLoS ONE. 14(1). e0208958–e0208958. 65 indexed citations

Mosedale, Merrie, J. Scott Eaddy, O. Joseph Trask, et al.. (2017). miR-122 Release in Exosomes Precedes Overt Tolvaptan-Induced Necrosis in a Primary Human Hepatocyte Micropatterned Coculture Model. Toxicological Sciences. 161(1). 149–158. 40 indexed citations

Lu, Jingtao, et al.. (2015). Morphological and Functional Characterization and Assessment of iPSC-Derived Hepatocytes forIn VitroToxicity Testing. Toxicological Sciences. 147(1). 39–54. 86 indexed citations

Thulin, Petra, Gunnar Nordahl, Marcus Gry, et al.. (2013). Keratin‐18 and micro RNA ‐122 complement alanine aminotransferase as novel safety biomarkers for drug‐induced liver injury in two human cohorts. Liver International. 34(3). 367–378. 89 indexed citations

10.

Rochon, James, Petr Protiva, Leonard B. Seeff, et al.. (2008). Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug‐induced liver injury†‡. Hepatology. 48(4). 1175–1183. 134 indexed citations

11.

Bushel, Pierre R., Alexandra N. Heinloth, Lingkang Huang, et al.. (2007). Blood gene expression signatures predict exposure levels. Proceedings of the National Academy of Sciences. 104(46). 18211–18216. 90 indexed citations

12.

Watkins, Paul B., et al.. (2007). Clinical Pattern of Zileuton-Associated Liver Injury. Drug Safety. 30(9). 805–815. 43 indexed citations

13.

Chalasani, Naga, Robert J. Fontana, Paul B. Watkins, et al.. (2006). Drug Induced Liver Injury Network (DILIN) Prospective Study. The American Journal of Gastroenterology. 101. S169–S169. 8 indexed citations

14.

Paine, Mary F., et al.. (2004). DO MEN AND WOMEN DIFFER IN PROXIMAL SMALL INTESTINAL CYP3A OR P-GLYCOPROTEIN EXPRESSION?. Drug Metabolism and Disposition. 33(3). 426–433. 89 indexed citations

15.

Lau, Wei C., et al.. (2003). Clopidogrel nonresponders discovered during point-of-care platelet aggregation testing. Journal of the American College of Cardiology. 41(6). 225–226. 4 indexed citations

16.

Schmiedlin‐Ren, Phyllissa, et al.. (2001). The furocoumarin 6',7'-dihydroxybergamottin (DHB) accelerates CYp3A4 degradation via the ubiquitin-proteasomal pathway.. Drug Metabolism Reviews. 33. 97. 6 indexed citations

17.

Fontana, Robert J., D. Kim Turgeon, Thomas F. Woolf, et al.. (1996). The Caffeine Breath Test Does Not Identify Patients Susceptible to Tacrine Hepatotoxicity. Hepatology. 23(6). 1429–1435. 16 indexed citations

18.

Watkins, Paul B.. (1993). Omeprazole induction of cytochrome P-450IA2: The importance of selecting the appropriate human model. Hepatology. 17(4). 748–750. 1 indexed citations

19.

Hunt, Christine M., Paul B. Watkins, Paul Saenger, et al.. (1992). Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol. Clinical Pharmacology & Therapeutics. 51(1). 18–23. 95 indexed citations

20.

Watkins, Paul B., et al.. (1989). Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients.. Journal of Clinical Investigation. 83(2). 688–697. 316 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact